ACSL3 and neoplasm: In mouse pancreatic cancer, Acsl3 deletion triggered reduced tumor cell proliferation, in part by impairing the production of the pro-fibrotic plasminogen activator inhibitor-1 (PAI-1), decreasing desmoplasia and immunosuppression [10].